Downregulation of adipose triglyceride lipase by EB viral-encoded LMP2A links lipid accumulation to increased migration in nasopharyngeal carcinoma.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
12 2020
Historique:
received: 01 11 2019
revised: 02 07 2020
accepted: 12 10 2020
pubmed: 17 10 2020
medline: 4 9 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common human cancers in South-East Asia exhibiting typical features of lipid accumulation. EBV-encoded latent membrane protein 2A (LMP2A) is expressed in most NPCs enhancing migration and invasion. We recently showed an increased accumulation of lipid droplets in NPC, compared with normal nasopharyngeal epithelium. It is important to uncover the mechanism behind this lipid metabolic shift to better understand the pathogenesis of NPC and provide potential therapeutic targets. We show that LMP2A increased lipid accumulation in NPC cells. LMP2A could block lipid degradation by downregulating the lipolytic gene adipose triglycerol lipase (ATGL). This is in contrast to lipid accumulation due to enhanced lipid biosynthesis seen in many cancers. Suppression of ATGL resulted in enhanced migration in vitro, and ATGL was found downregulated in NPC biopsies. The reduced expression level of ATGL correlated with poor overall survival in NPC patients. Our findings reveal a new role of LMP2A in lipid metabolism, correlating with NPC patient survival depending on ATGL downregulation.

Identifiants

pubmed: 33064888
doi: 10.1002/1878-0261.12824
pmc: PMC7718958
doi:

Substances chimiques

EBV-associated membrane antigen, Epstein-Barr virus 0
Lipids 0
Viral Matrix Proteins 0
Lipase EC 3.1.1.3
PNPLA2 protein, human EC 3.1.1.3
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3234-3252

Informations de copyright

© 2020 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

Lancet. 1964 Mar 28;1(7335):702-3
pubmed: 14107961
PLoS Pathog. 2012;8(8):e1002866
pubmed: 22916018
J Pathol. 2005 Jun;206(2):214-9
pubmed: 15880754
Cell Host Microbe. 2014 Mar 12;15(3):266-82
pubmed: 24629334
Clin Cancer Res. 2003 Jun;9(6):2204-12
pubmed: 12796387
Gut. 2012 Oct;61(10):1454-64
pubmed: 22234980
J Virol. 2017 Feb 28;91(6):
pubmed: 28053105
Oncotarget. 2015 Dec 1;6(38):41077-91
pubmed: 26506425
Oncogene. 2016 Aug 11;35(32):4155-64
pubmed: 26686092
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Oncogene. 2019 Mar;38(11):1860-1875
pubmed: 30367149
Lab Invest. 1993 Jun;68(6):716-27
pubmed: 7685844
J Virol. 2012 Oct;86(19):10308-20
pubmed: 22837212
BMC Cancer. 2017 Sep 6;17(1):631
pubmed: 28877685
Nat Protoc. 2018 Apr;13(4):633-651
pubmed: 29494574
Mod Pathol. 2005 Aug;18(8):1107-12
pubmed: 15920554
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Cancer. 2018 May 15;17(1):90
pubmed: 29764424
Anticancer Res. 2004 Nov-Dec;24(6):4169-73
pubmed: 15736468
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Trends Microbiol. 2015 Dec;23(12):789-798
pubmed: 26439298
Nat Rev Mol Cell Biol. 2008 Feb;9(2):112-24
pubmed: 18216768
Oncogene. 2014 Sep 11;33(37):4568-78
pubmed: 24662831
Biol Open. 2017 Jun 15;6(6):914-922
pubmed: 28512118
J Proteome Res. 2018 Apr 6;17(4):1415-1425
pubmed: 29457907
Cell Metab. 2013 Aug 6;18(2):153-61
pubmed: 23791484
Science. 2012 Aug 31;337(6098):1062-5
pubmed: 22936770
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
J Pathol. 2015 Oct;237(2):238-48
pubmed: 26096068
PLoS One. 2011 Apr 26;6(4):e19137
pubmed: 21541331
Sci Sin. 1978 Jan-Feb;21(1):127-34
pubmed: 206962
Cell. 2010 Jan 8;140(1):49-61
pubmed: 20079333
Med Oncol. 2015 Jan;32(1):391
pubmed: 25433947
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
PLoS Pathog. 2013;9(4):e1003266
pubmed: 23592989
J Hepatol. 2008 Mar;48(3):471-8
pubmed: 18191271
J Virol. 2001 Nov;75(22):10941-9
pubmed: 11602734
J Virol. 2015 Apr;89(8):4092-101
pubmed: 25673715
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3704-13
pubmed: 25120746
Gut. 2010 Sep;59(9):1279-87
pubmed: 20660700
Elife. 2017 Dec 19;6:
pubmed: 29256392
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Nat Commun. 2017 Mar 22;8:14859
pubmed: 28327588
Nat Cell Biol. 2007 Sep;9(9):1089-97
pubmed: 17721513
Infect Agent Cancer. 2014 Nov 17;9(1):38
pubmed: 25473414
Trends Biochem Sci. 2010 Aug;35(8):427-33
pubmed: 20570523
Semin Cancer Biol. 2002 Dec;12(6):421-9
pubmed: 12450728
Lancet Oncol. 2012 Jun;13(6):607-15
pubmed: 22575588
J Pathol. 1991 Sep;165(1):17-24
pubmed: 1659626
Biochem Biophys Res Commun. 2015 Nov 6;467(1):121-7
pubmed: 26403972
PLoS Pathog. 2013;9(8):e1003497
pubmed: 23935494
Anal Chem. 2012 Jun 5;84(11):5035-9
pubmed: 22533540
Oncogene. 2015 Aug 20;34(34):4491-9
pubmed: 25531330
Virol Sin. 2015 Apr;30(2):107-21
pubmed: 25910483
PLoS One. 2017 Apr 12;12(4):e0174968
pubmed: 28403150
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
Cell Death Dis. 2017 Jun 1;8(6):e2838
pubmed: 28569772
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):880-899
pubmed: 30367950
Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
pubmed: 11413487
Nat Rev Cancer. 2016 Dec;16(12):789-802
pubmed: 27687982
Nat Rev Cancer. 2013 Apr;13(4):258-71
pubmed: 23486238
Carcinogenesis. 2014 Jul;35(7):1592-601
pubmed: 24632494
Curr Opin Virol. 2011 Jul;1(1):19-26
pubmed: 22440563
Trends Endocrinol Metab. 2016 Feb;27(2):105-117
pubmed: 26754340
Biochem Biophys Res Commun. 2019 May 14;512(4):806-811
pubmed: 30926171
EMBO Rep. 2006 Jan;7(1):106-13
pubmed: 16239926
Mol Cancer. 2017 Apr 11;16(1):76
pubmed: 28399876
Methods Mol Biol. 2017;1550:339-368
pubmed: 28188540
J Lipid Res. 2019 Jun;60(6):1069-1077
pubmed: 30918066
PLoS Pathog. 2010 Jun 03;6(6):e1000940
pubmed: 20532215
Oncotarget. 2016 Jun 7;7(23):33832-40
pubmed: 27213586
Mol Med Rep. 2013 Mar;7(3):731-41
pubmed: 23292678
Tumour Biol. 2015 Aug;36(8):5931-42
pubmed: 25724187
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Nat Med. 2013 Jun;19(6):722-9
pubmed: 23708292

Auteurs

Shixing Zheng (S)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Liudmila Matskova (L)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
The School of Life Sciences, Baltic Federal University, Kaliningrad, Russia.

Xiaoying Zhou (X)

Scientific Research Center, Life Science Institute, Guangxi Medical University, Nanning, China.

Xue Xiao (X)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Guangwu Huang (G)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Zhe Zhang (Z)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Ingemar Ernberg (I)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH